Cost Reduction in Cell and Gene Therapy 2023: Featuring Key Players Roche, Bayer and Novartis, as well as Start-Ups Dyno Therapeutics and Capsigen
Saturday, February 4, 2023
DUBLIN, Jan. 6, 2023 /PRNewswire/ -- The "Cost Reduction in Cell and Gene Therapy" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
With the advancement of delivery vectors and gene editing technologies, cell and gene therapies have been proven to be a very real and affordable solution to otherwise many untreatable diseases. It is now possible to add, silence, replace, and modify genes to treat diseases like neuromuscular disorders, immunodeficiencies, and ocular and liver diseases as well as develop enhanced cells for the treatment of diseases like cancer.
Although cell and gene therapies show great promise, the full extent of their clinical impact in the long term is not yet certain. Researchers and scientists from the past decades have been actively working on developing cell/gene-mediated innovative and promising solutions.
Achieving cost efficiency while developing an effective cell and gene therapy still remains one of the major challenges to address. Several biotherapeutic companies are developing strategies to reduce cost and time. Various strategies such as single-use bioreactors, engineered vectors, and automating the vector design process are being recently utilized to significantly reduce manufacturing costs.
Key Highlights of Report:
The publisher has prepared an exclusive syndicate report on the topic "Cost Reduction Technologies for Cell and Gene Therapies", this report covers all the technologies being explored across different processes of upstream, downstream, packaging, and storage of cell and gene therapy products, opportunities for different type of players such as CGT manufacturers, CRO/CDMOs, raw material providers, tools and technology providers, and others along with an opportunity matrix and expert recommendations.
The publisher forecasts a considerable trend for the integration of AI/ML models in the designing and manufacturing of cell and gene therapy products. AI models and ML approaches can effectively accelerate the R&D for cell and gene therapies by saving time and avoiding the need to undertake unnecessary costly experiments. AI and advanced analytics are poised to become vital enablers for boosting the return on R&D spending in the cell and gene therapy value chain by increasing speed, reducing clinical failures, cutting costs across the manufacturing value chain, and enabling sustainable technology platforms.
Many leading players such as Roche, Bayer, and Novartis are incorporating the power of AI to analyse cellular and genetic data for developing therapeutic formulations in the domain. Various Start-Ups such as Dyno Therapeutics, Capsigen are effectively utilizing artificial intelligence for vector designing and engineering in the cell and gene therapy domain.
Key Topics Covered:
1 Introduction & Overview
-- Selected Industry Developments: Cost Reduction for Cell & Gene Therapy
-- Recent Advances for Cost Reduction or Improving Process Efficiency
-- Companies Working Around Different Applications of Cost-Effective
Strategies for Cell/ Gene Therapy Development and Manufacturing
2 Executive Summary
-- Overview & Comparative Assessment of Key Technology Clusters
-- Key Business Takeaways
-- Key Technology Takeaways
3 Technology Landscape
-- Recently Explored Cost-Effective Technologies
-- Integration of Ai & Ml Models - Ai-Based Vector Engineering, Promoter
Designing, Purification Methodologies, Etc.
-- Computer-Implemented Strategies in Vector Development-
In-Silico-Mediated Sequence Characterization of the Cell Line,
Cryo-Electron Microscopy Platforms, Etc.
-- Advances in Scaling & Purification Technologies -Nanofiber-Mediated
Purification, Single-Use Bioreactors, Fluid Communication Systems, Etc.
-- Novel Delivery Systems -Exosomes Mediated Gene/Cell Transfer, Modified
Vectors, Polymeric Particles, Etc.
-- Other Promising Technologies
-- Cost-Effective Technologies for Upstream Processes
-- Raw Material Preparation for Cell/ Gene Therapy (Cell Line Development,
Vial Preparation)
-- Vector Designing
-- Cell Culturing and Scaling Up Procedure
-- Other Processes
-- Cost-Effective Technologies for Downstream Processes
-- Purification and Cell Harvesting Methodologies (Utilizing Advanced
Chromatography, Membrane, and Automated Technologies for Cell
Harvesting)
-- Manufacturing & Packaging of Therapeutic Formulation
-- Other Processes
4 Competitive Intelligence
-- Leading Companies and Their Activities for Achieving Cost Efficiency in
the Cgt Domain
-- Start-Ups and Their Activities for Achieving Cost Efficiency in the Cgt
Domain
-- Investment Deals and Fundings
-- Strategic Activities and Future Plans of Key Companies for Achieving
Cost Efficiency
5 Commercial Analysis: Technologies & Opportunities For:
-- Cell & Gene Therapy Manufacturers
-- CROs/CDMOs
-- Raw Material Manufacturers
-- Tool & Technology Providers
6 Feasibility Analysis
-- Market Readiness of Top Technologies
-- Scalability & Used Cases of Top Technologies
7 IEBS Recommendation & Opportunity Matrix
For more information about this report visit https://www.researchandmarkets.com/r/yqbwkh
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/cost-reduction-in-cell-and-gene-therapy-2023-featuring-key-players-roche-bayer-and-novartis-as-well-as-start-ups-dyno-therapeutics-and-capsigen-301714596.html
SOURCE Research and Markets
|
|
|
|
|
 |
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Marketing Evolution Announces New Investment Led by Insight Partners to Power AI-Ready Marketing Data for the Agentic Era | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
|
